ReviewJournal of nanobiotechnology2025
The develop of persistent luminescence nanoparticles with excellent performances in cancer targeted bioimaging and killing: a review.
Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Rational Design and Development of Organic Afterglow Nanoparticles for Image-Guided Interventions.Small methods · 2026Review
- Illumination of Targeting Nanotherapeutics with Precision Eyes: From Optical to Radio-nanotheranostics.Theranostics · 2026Review
- Engineered Exosomes: Advances in Therapeutic Applications for Otolaryngology-Head and Neck Diseases.International journal of nanomedicine · 2026Review
- ZnO and ZnS Hybrid Film Enhances the Bone Regeneration Performance of Zinc-Based Implants.ACS omega · 2025Article
- Research Progress of Persistent Luminescence Nanoparticles in Biological Detection Imaging and Medical Treatment.Materials (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The use of fluorescent nanomaterials in tumor imaging and treatment effectively avoids the original limitations of traditional tumor clinical diagnostic methods. The PLNPs emitted persistent luminescence after the end of excitation light. Owing to their superior optical properties, such as a reduced laser irradiation dose, spontaneous fluorescence interference elimination, and near-infrared imaging, PLNPs show great promise in tumor imaging. Moreover, they also achieve excellent anti-tumor therapeutic effects through surface modification and drug delivery. However, their relatively large size and limited surface modification capacity limit their ability to kill tumors effectively enough for clinical applications. Thus, this article reviews the synthesis and modification of PLNPs and the research progress in targeted tumor imaging and tumor killing. We also discuss the challenges and prospects of their future applications in these fields. This review has value for accelerating the design of PLNPs based platform for cancer diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.